
Bristol Myers Squibb Company (NYSE:BMY – Free Report) – Analysts at Zacks Research boosted their Q3 2027 EPS estimates for shares of Bristol Myers Squibb in a research note issued to investors on Wednesday, November 11th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $1.74 per share for the quarter, up from their prior forecast of $1.55. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.46 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.41 EPS, Q1 2028 earnings at $1.36 EPS, Q2 2028 earnings at $1.25 EPS and Q3 2028 earnings at $1.16 EPS.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period last year, the business posted $1.63 earnings per share.
Several other analysts also recently weighed in on BMY. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $76.00 price target on shares of Bristol Myers Squibb in a research report on Monday, October 12th. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Daiwa Securities Group upped their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Truist Financial set a $70.00 price objective on Bristol Myers Squibb in a research report on Friday, October 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $65.46.
Bristol Myers Squibb Price Performance
NYSE BMY opened at $61.32 on Monday. Bristol Myers Squibb has a twelve month low of $45.26 and a twelve month high of $68.64. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The stock has a market capitalization of $125.35 billion, a PE ratio of 10.10, a P/E/G ratio of 0.32 and a beta of 0.20. The stock has a 50-day simple moving average of $61.75 and a 200 day simple moving average of $60.39.
Institutional Trading of Bristol Myers Squibb
A number of hedge funds have recently modified their holdings of BMY. Financial Freedom LLC acquired a new position in shares of Bristol Myers Squibb in the third quarter valued at $26,000. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb in the second quarter worth $27,000. Addison Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth $32,000. William Mack & Associates Inc. acquired a new stake in Bristol Myers Squibb during the third quarter worth $35,000. Finally, Cavanaugh Group Inc. acquired a new stake in Bristol Myers Squibb during the third quarter worth $36,000. Institutional investors own 76.41% of the company’s stock.
Insider Transactions at Bristol Myers Squibb
In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Julia Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is currently owned by corporate insiders.
Bristol Myers Squibb Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.
Trending Headlines about Bristol Myers Squibb
Here are a few of the latest headlines about BMY:
- Positive Sentiment: Bristol Myers will sponsor a Phase 1/2 study testing Erasca’s ERAS-0015 with BMS’s navlimetostat in patients with MTAP-deleted pancreatic cancer; Erasca will supply ERAS-0015. The partnership could advance a combination approach in a difficult-to-treat cancer, although it remains early-stage and no financial terms or clinical results were disclosed. Erasca clinical collaboration announcement
- Neutral Sentiment: Revolution Medicines received European approval for Rasonque in metastatic pancreatic cancer. This adds a competing treatment in the broader indication, but the article does not establish a direct impact on BMS’s investigational combination. Rasonque EU approval report
- Neutral Sentiment: BMY was described as a trending stock, reflecting investor attention rather than a new business development or a clear explanation for its trading direction. BMY trending-stock report
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Further Reading
- Five stocks we like better than Bristol Myers Squibb
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
